Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 23, 2026

Buy 3 Giant Mobile Payments Stocks With Solid Short-Term Price Upside

View original at finance.yahoo.com
Buy 3 Giant Mobile Payments Stocks With Solid Short-Term Price Upside The rapid shift from cash to digital transactions, driven by a push toward convenience and security, has led to meteoric growth in mobile payments…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • JPMorgan Chase carries a Zacks Rank #2 (Buy)

    60% confidence
  • Net interest income expected to increase 9% in 2026

    60% confidence
  • Mobile payments market is anticipated to experience meteoric growth in the long term

    60% confidence
  • Mobile payments market anticipated to experience meteoric growth in the long term

    60% confidence
  • Plans to allocate $19.8 billion toward tech initiatives in 2026

    60% confidence
  • Jack Henry & Associates Inc. carries a Zacks Rank #2 (Buy)

    60% confidence
  • JPMorgan Chase, Intuit, and Jack Henry & Associates are recommended as mobile payments stocks to buy and hold for the long term

    60% confidence
  • Intuit Inc. carries a Zacks Rank #2 (Buy)

    60% confidence
  • Zacks Consensus Estimate for JPMorgan's current year earnings has improved 1.3% in the last 30 days

    60% confidence
  • Net interest income expected to increase 9% for 2026

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com